Hepatitis C Vaccine

Second clinical phase IIb trial of the hepatitis C E1 vaccine extended

Published in Vaccine Weekly, August 3rd, 2005

Innogenetics announced the results of the investigators' meeting held on June 24 to plan the next steps in the clinical program for its E1-based therapeutic vaccine candidate in patients chronically infected with hepatitis C virus (HCV).

Based on a thorough review of the first phase IIb trial (Study 916) results, the investigators confirmed their interest in extending the treatment period of the ongoing second phase IIb trial employing a higher dose of E1 (Study 918). With a total duration of 3 years, final results of the second phase IIb trial are now expected to be announced in the second half of 2007.

On June 1, Innogenetics announced the results...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-08-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry